Gsk (GSK) Invested Capital (2013 - 2026)
Gsk (GSK) posted Invested Capital of $71.4 billion for Q4 2025, up 10.28% on a QoQ basis from $64.7 billion in Q4 2024, and up 10.28% year-over-year from $64.7 billion in Q4 2024.
Gsk (GSK) has 11 years of Invested Capital data on file, last reported at $71.4 billion in Q4 2025.
- In Q4 2025, Invested Capital rose 10.28% year-over-year to $71.4 billion; the TTM figure through Dec 2025 stood at $71.4 billion (up 10.28% YoY), while the FY2025 annual figure was $71.4 billion, up 10.28% from the prior year.
- Invested Capital improved to $71.4 billion in Q4 2025, from $64.7 billion in the prior quarter.
- Across five years, Invested Capital topped out at $71.4 billion in Q4 2025 and bottomed at $32.6 billion in Q4 2022.
- A 5-year average of $50.2 billion and a median of $47.0 billion in 2021 frame the typical range for Invested Capital.
- Annual changes were most pronounced in 2022 — Invested Capital slumped 30.69% — and 2024, when it jumped 83.66%.
- Year by year, Invested Capital stood at $47.0 billion in 2021, then slumped by 30.69% to $32.6 billion in 2022, then advanced by 8.07% to $35.2 billion in 2023, then jumped by 83.66% to $64.7 billion in 2024, then grew by 10.28% to $71.4 billion in 2025.
- The last three Invested Capital figures came in at $71.4 billion (Q4 2025), $64.7 billion (Q4 2024), and $35.2 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 72.79 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 98.65 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -6.66 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 48.32 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 66.51 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 45.69 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 90.96 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 64.21 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 71.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.12 Bn |
| Dec 31, 2025 | 71.36 Bn |
| Sep 30, 2025 | -7.48 Bn |
| Jun 30, 2025 | -7.26 Bn |
| Mar 31, 2025 | -7.37 Bn |
| Dec 31, 2024 | 64.71 Bn |
| Sep 30, 2024 | -7.82 Bn |
| Jun 30, 2024 | -7.63 Bn |
| Mar 31, 2024 | -7.59 Bn |
| Dec 31, 2023 | 35.23 Bn |
| Sep 30, 2023 | -6.95 Bn |
| Jun 30, 2023 | -6.61 Bn |
| Mar 31, 2023 | -6.83 Bn |
| Dec 31, 2022 | 32.60 Bn |
| Sep 30, 2022 | -7.50 Bn |
| Jun 30, 2022 | -6.89 Bn |
| Mar 31, 2022 | -6.97 Bn |
| Dec 31, 2021 | 47.04 Bn |
| Sep 30, 2021 | -6.96 Bn |
| Jun 30, 2021 | -7.01 Bn |
| Mar 31, 2021 | -6.98 Bn |
| Dec 31, 2020 | 46.70 Bn |
| Jun 30, 2020 | -6.24 Bn |
| Mar 31, 2020 | -6.29 Bn |
| Dec 31, 2019 | 47.08 Bn |
| Sep 30, 2019 | -6.52 Bn |
| Jun 30, 2019 | -6.70 Bn |
| Mar 31, 2019 | -6.73 Bn |
| Dec 31, 2018 | 34.36 Bn |
| Sep 30, 2018 | -7.06 Bn |
| Jun 30, 2018 | -7.31 Bn |
| Mar 31, 2018 | -6.79 Bn |
| Dec 31, 2017 | 22.13 Bn |
| Sep 30, 2017 | -6.54 Bn |
| Jun 30, 2017 | -6.63 Bn |
| Mar 31, 2017 | -6.44 Bn |
| Dec 31, 2016 | 23.33 Bn |
| Sep 30, 2016 | -6.31 Bn |
| Jun 30, 2016 | -6.49 Bn |
| Dec 31, 2015 | 29.75 Bn |
| Dec 31, 2014 | 30.60 Bn |
| Jun 30, 2014 | -1.93 Bn |
| Dec 31, 2013 | -1.77 Bn |
| Jun 30, 2013 | -1.34 Bn |